Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;15(1-2):41-44.
doi: 10.3121/cmr.2017.1349.

Recurrent Thrombosis in Patients with Antiphospholipid Syndrome Receiving Newer Oral Anticoagulants: A Case Report and Review of Literature

Akanksha Joshi  1 , Jason Hong  2 , Chokkalingam Siva  3
Affiliations
Review

Recurrent Thrombosis in Patients with Antiphospholipid Syndrome Receiving Newer Oral Anticoagulants: A Case Report and Review of Literature

Akanksha Joshi et al. Clin Med Res. 2017 Jun.

Abstract

We present the case of a patient with primary APS who had a recurrence of thrombotic event while on treatment with rivaroxaban and had to be restarted on warfarin. The current literature on recurrence of thrombotic events in patients with antiphospholipid syndrome (APS) treated with newer oral anticoagulants (NOAC) is also reviewed. Relevant case reports and case series were identified by searching the Medline database using the key words antiphospholipid syndrome, anticoagulants and names of the NOACs, and data on individual patients was abstracted. We identified several reports on the failure of newer anticoagulants in APS, as well as cases and clinical trial results reporting efficacy. We conclude that treatment strategies for APS should be tailored cautiously when using NOACs.

Keywords: Anti-cardiolipin antibodies; Anti-phospholipid Syndrome; Anti-ß2-glycoprotein antibodies; Anticoagulants; Newer oral anticoagulant; Rivaroxaban; Warfarin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Transthoracic echocardiogram revealed a right atrial thrombus without evidence of a patent foramen ovale.
Figure 2
Figure 2
Transesophageal echocardiogram confirmed right atrial thrombus without evidence of a patent foramen ovale.
See this image and copyright information in PMC

References

    1. Son M, Wypasek E, Celinska-Lowenhoff M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. Thromb Res 2015;135:1035–1036. - PubMed
    1. Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 2014;89:1017. - PubMed
    1. Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 2014;112:947–950. - PubMed
    1. Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol 2016;35:801–805. - PubMed
    1. Vergallo R, Aguirre AD, Abtahian F, Minami Y, Soeda T, Chatzizisis YS, Croce K, Jang IK. Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome. Thromb Haemost 2016;115:237–239. - PubMed

MeSH terms